Fludarabine, Cyclophosphamide, FATE-NK100 and Aldesleukin in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Inclusion Criteria

• Recurrent epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer meeting one of the following minimal prior treatment requirement (no limit to the maximum number of prior treatments): * Platinum resistant: may receive FATE-NK100 as 2nd line (as 1st salvage therapy) with platinum resistant is defined as disease that has responded to initial chemotherapy but demonstrates recurrence within a relatively short period of time (< 6 months) following the completion of treatment * Platinum sensitive: may receive FATE-NK100 as 3rd line therapy (as 2nd salvage therapy) with platinum sensitive is defined as the recurrence of active disease in a patient who has achieved a documented response to initial platinum-based treatment and has been off therapy for an extended period of time (>= 6 months)
• Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 limited to the abdomen and pelvis
• Available HLA-matched or better but not fully HLA-matched (2/4 or 3/4 antigens) related donor (aged 18 to 75 years) with donor/recipient match based on a minimum of intermediate resolution deoxyribonucleic acid (DNA) based class I typing of the A and B locus who is cytomegalovirus (CMV) seropositive
• Gynecologic Oncology Group (GOG) performance status 0, 1, or 2
• Platelets >= 80,000 x 10^9/L unsupported by transfusions (within 14 days of study registration)
• Hemoglobin >= 9 g/dL, unsupported by transfusions (within 14 days of study registration)
• Absolute neutrophil count (ANC) >= 1000 x 10^9/L, unsupported by granulocyte colony-stimulating factor (G-CSF) or granulocytes (within 14 days of study registration)
• Estimated glomerular filtration rate (eGFR) >= 50 mL/min/1.73m^2 per current institutional calculation formula (within 14 days of study registration)
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of institutional normal (within 14 days of study registration)
• Oxygen saturation >= 90% on room air; pulmonary function test (PFT)’s required only if symptomatic or prior known impairment - must have pulmonary function > 50% corrected carbon monoxide diffusing capability (DLCO) and forced expiratory volume in 1 second (FEV1) (within 28 days of study registration)
• Left ventricular ejection fraction (LVEF) >= 40% by echocardiography, multigated acquisition (MUGA), or cardiac magnetic resonance imaging (MRI); no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities (within 28 days of study registration)
• Able to be off prednisone or other immunosuppressive medications for at least 3 days prior to FATE-NK100 cell infusion (excluding preparative regimen premedications)
• Agrees to the placement of an intraperitoneal port before the start of chemotherapy and remains in place through day 28 or longer
• Washout period of at least 14 days after any approved or experimental tumor directed therapy prior to start of cyclophosphamide and fludarabine
• If history of brain metastases must be stable for at least 3 months after treatment – a brain computed tomography (CT) scan or MRI is only be required in subjects with known brain metastases at the time of enrollment or in subjects with clinical signs or symptoms suggestive of brain metastases
• Voluntary written consent prior to the performance of any research related procedures

Exclusion Criteria

• Untreated brain metastases
• Myocardial infraction (MI) within the previous 6 months
• Active autoimmune disease requiring systemic immunosuppressive therapy
• History of severe asthma and currently on chronic systemic medications (mild asthma requiring inhaled steroids only is eligible)
• New or progressive pulmonary infiltrates on screening chest X-ray or chest CT scan unless cleared for study by pulmonary; infiltrates attributed to infection must be stable/improving (with associated clinical improvement) after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections)
• Uncontrolled bacterial, fungal or viral infections with progression of clinical symptoms despite therapy
• Known history of human immunodeficiency virus (HIV) positivity or active hepatitis C or B - chronic asymptomatic viral hepatitis is allowed
• Received any investigational agent within the 14 days before the start of study treatment (1st dose of fludarabine)
• Disease outside of the peritoneal cavity